Steph & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Steph & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-330	Closed	-$36K	–	248
2023 Q1	$36K	Sell	330 -810	-71%	-$89.5K	0.02%	167
2022 Q4	$130K	Sell	1,140 -1,000	-47%	-$83.1K	0.08%	127
2022 Q3	$132K	Buy	2,140 +77	+4%	+$5.38K	0.09%	115
2022 Q2	$165K	Buy	2,063 +263	+15%	+$24.9K	0.1%	110
2022 Q1	$189K	Buy	1,800 +381	+27%	+$37.1K	0.11%	99
2021 Q4	$153K	Hold	1,419	–	–	0.09%	127
2021 Q3	$155K	Hold	1,419	–	–	0.1%	112
2021 Q2	$133K	Buy	1,419 +453	+47%	+$41.7K	0.09%	121
2021 Q1	$89K	Buy	966 +163	+20%	+$13.8K	0.06%	142
2020 Q4	$59K	Buy	+803	New	+$59.7K	0.05%	152

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Steph & Co's HZNP Position: Q2 2023 in Review

Steph & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 330 shares — an estimated $36K sold.

Steph & Co first reported a position in HZNP in Q4 2020 and held it in 10 quarters. The position peaked at $189K in Q1 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Steph & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Steph & Co sold 330 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $36K.
Steph & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 10 quarters.
Steph & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $189K in Q1 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Steph & Co's 13F filing for Q2 2023, filed 14 Jul 2023.